India's Supreme Court this week denied a patent sought 7 years ago by Novartis, the Swiss pharma company, for a crystal (pill) form of its celebrated anticancer drug Glivec (also known as Gleevec). Groups pushing for low-cost medicines, such as Doctors Without Borders, cheered, while biotech and pharmaceutical groups warned of a possible chill in new drug development.
展开▼
